论文部分内容阅读
目的观察谷参肠安(复方谷氨酰胺肠溶胶囊)口服治疗活动期溃疡性结肠炎(UC)的疗效及安全性,并进一步探讨其对肠黏膜细胞因子的影响。方法活动期UC患者76例,随机分为2组。对照组(36例)口服柳氮磺胺吡啶(或美沙拉嗪),同时用琥珀酸氢化考的松及庆大霉素、蒙脱石散保留灌肠,每晚1次;治疗组(40例)在上述治疗基础上,口服谷参肠安胶囊0.6g,每天3次。治疗2个月后评价2组疗效,主要症状和结肠镜变化情况,免疫组化法检测患者肠黏膜局部细胞因子IL-10和IL-18的变化。结果治疗后两组临床表现均明显好转,且治疗组优于对照组,2组比较,差异有统计学意义(P<0.05)。疾病活动指数(DAI)降低(P<0.05),降低幅度治疗组优于对照组(t=5.05,P<0.01);治疗后黏膜细胞因子IL-10的水平升高,IL-18降低,治疗组均优于对照组(P<0.05)。结论谷参肠安口服并联合琥珀酸氢化考的松及庆大霉素保留灌肠治疗活动期UC近期疗效明显优于只用琥珀酸氢化考的松及庆大霉素保留灌肠,且无明显不良反应。
Objective To observe the efficacy and safety of oral administration of Gansu Changan (compound glutamine enteric-coated capsules) in the treatment of active ulcerative colitis (UC), and further investigate its effect on intestinal mucosal cytokines. Methods 76 patients with active UC were randomly divided into two groups. The control group (36 cases) was orally given sulfasalazine (or mesalazine), while the hydrocortisone and gentamicin succinate, montmorillonite powder retention enema, night 1; treatment group (40 cases) On the basis of the above treatment, oral ginseng intestinal capsules 0.6g, 3 times a day. After 2 months of treatment, the curative effect, the main symptoms and the changes of colonoscopy were evaluated. The changes of intestinal mucosal IL-10 and IL-18 in the intestinal mucosa were detected by immunohistochemistry. Results After treatment, the clinical manifestations of both groups were significantly improved, and the treatment group was superior to the control group. There was significant difference between the two groups (P <0.05). The disease activity index (DAI) decreased (P <0.05), and the decreased amplitude in the treatment group was better than that in the control group (t = 5.05, P <0.01). After treatment, the levels of mucosal cytokine IL- Group were better than the control group (P <0.05). Conclusions Guizhi Changan oral combined with hydrocortisone hydrocortisone and gentamicin retention enema in the treatment of active UC was significantly better than the effect of only hydrocortisone succinate and gentamicin retention enema, and no significant adverse reaction.